OptimizeRx Corp. (OPRX) P/E Ratio History
Deep ValueTrading at 28.1x · 17th percentile of 5-year range · Significant discount to historical valuation · Data 2013–2026
Loading P/E history...
P/E Ratio Analysis
As of September 24, 2026, OptimizeRx Corp. (OPRX) trades at a price-to-earnings ratio of 28.1x, with a stock price of $7.60 and trailing twelve-month earnings per share of $0.24.
The current P/E is 97% below its 5-year average of 852.2x. Over the past five years, OPRX's P/E has ranged from a low of 17.7x to a high of 3675.1x, placing the current valuation at the 17th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, OPRX trades at a 19% premium to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 167.0x.
Relative to the broader market, OPRX trades roughly in line with the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our OPRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
OPRX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
OPRX P/E vs Peers
Patient Engagement, Intake and Payments peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $5B | 27.1 | 0.52Best | -12% | |
| $2B | 106.1 | - | +64% | |
| $1B | 6.1Lowest | 0.59 | +817%Best | |
| $2B | 39.7 | 5.93 | +14% | |
| $44B | 49.8 | 2.74 | +26% | |
| $105B | 22.9 | - | +49% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
OPRX Historical P/E Data (2013–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $5.72 | $0.23 | 24.5x | -97% |
| FY2026 Q1 | - | $6.28 | $0.35 | 17.7x | -98% |
| FY2025 Q4 | Dec 31 2025 | $12.26 | $0.26 | 47.0x | -94% |
| FY2021 Q4 | Dec 31 2021 | $62.11 | $0.02 | 3675.1x | +331% |
| FY2021 Q3 | - | $85.55 | $0.06 | 1366.6x | +60% |
| FY2021 Q2 | Jun 30 2021 | $61.90 | $0.04 | 1532.2x | +80% |
| FY2019 Q2 | Jun 30 2019 | $16.20 | $0.04 | 391.3x | -54% |
| FY2019 Q1 | Mar 31 2019 | $12.72 | $0.03 | 405.1x | -52% |
| FY2018 Q4 | Dec 31 2018 | $10.97 | $0.01 | 945.7x | +11% |
| FY2013 Q4 | - | $5.10 | $0.00 | 1342.1x | +57% |
| FY2013 Q3 | Sep 30 2013 | $3.54 | $0.04 | 95.9x | -89% |
| FY2013 Q2 | Jun 30 2013 | $4.68 | $0.01 | 383.6x | -55% |
Average P/E for displayed period: 852.2x
OPRX Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
OPRX — Frequently Asked Questions
Quick answers to the most common questions about buying OPRX stock.
What is OPRX's P/E ratio?
OptimizeRx Corp. (OPRX) trailing twelve-month P/E ratio is 28.1x, based on TTM diluted EPS of $0.24. The 5-year average P/E is 852.2x and the historical range spans 17.7x to 3675.1x.
Is OPRX stock overvalued or undervalued?
OPRX trades at 28.1x P/E, below its 5-year average of 852.2x. At the 17th percentile of its historical range (17.7x–3675.1x), the stock is priced at a discount to its own history.
Is OPRX stock expensive?
No, OPRX is not expensive on a historical basis. The current P/E of 28.1x is below the 5-year average of 852.2x and sits at the 17th percentile of its valuation range.
What is OPRX's historical P/E range?
Over the past 5 years, OPRX's P/E ratio has ranged from 17.7x to 3675.1x, with a median of 405.1x and an average of 852.2x. The current P/E of 28.1x places the stock at the 17th percentile of this range. Full historical data spans 2013–2026.
How does OPRX's P/E compare to the S&P 500?
OPRX trades at 28.1x P/E versus the S&P 500 median of 25.3x. The 11% premium to the market typically reflects higher expected earnings growth or quality.
How does OPRX's valuation compare to Healthcare peers?
OptimizeRx Corp. P/E of 28.1x compares to the Healthcare sector median of 23.7x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is OPRX's PEG ratio?
OPRX PEG ratio is N/A, based on a P/E of 28.1x and EPS growth of 124.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is OPRX's earnings yield?
OPRX earnings yield is 3.55%, the inverse of its 28.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.